| URN | urn:agi-llid:99 |
|---|---|
| Total Entities | 0 |
| Connectivity | 2919 |
| Name | Apoe |
| Description | apolipoprotein E |
| Notes | Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jul 2008] |
| GO Molecular Function | cholesterol transporter activity |
|---|---|
| lipid transporter activity | |
| phosphatidylcholine-sterol O-acyltransferase activator activity | |
| antioxidant activity | |
| lipid binding | |
| hydroxyapatite binding | |
| very-low-density lipoprotein particle receptor binding | |
| low-density lipoprotein particle receptor binding | |
| tau protein binding | |
| protein homodimerization activity | |
| protein heterodimerization activity | |
| phospholipid binding | |
| heparin binding | |
| beta-amyloid binding | |
| metal chelating activity | |
| lipoprotein particle binding |
| GO Cellular Component | extracellular region |
|---|---|
| extrinsic component of external side of plasma membrane | |
| nuclear envelope | |
| microtubule | |
| endocytic vesicle lumen | |
| low-density lipoprotein particle | |
| high-density lipoprotein particle | |
| chylomicron | |
| discoidal high-density lipoprotein particle | |
| very-low-density lipoprotein particle | |
| intermediate-density lipoprotein particle | |
| cell surface | |
| plasma membrane | |
| cytoplasm | |
| Golgi apparatus | |
| endoplasmic reticulum | |
| endosome | |
| lysosome | |
| late endosome | |
| early endosome | |
| dendrite | |
| neuronal cell body | |
| extracellular space |
| GO Biological Process | lipid metabolic process |
|---|---|
| small molecule metabolic process | |
| negative regulation of cholesterol biosynthetic process | |
| positive regulation of cGMP biosynthetic process | |
| negative regulation of MAP kinase activity | |
| cholesterol catabolic process | |
| positive regulation of nitric-oxide synthase activity | |
| positive regulation of cholesterol esterification | |
| triglyceride metabolic process | |
| retinoid metabolic process | |
| cholesterol metabolic process | |
| response to dietary excess | |
| negative regulation of blood coagulation | |
| negative regulation of platelet activation | |
| vasodilation | |
| cardiovascular system development | |
| artery morphogenesis | |
| oligodendrocyte differentiation | |
| positive regulation of axon extension | |
| regulation of axon extension | |
| neuron projection regeneration | |
| axon regeneration | |
| peripheral nervous system axon regeneration | |
| negative regulation of blood vessel endothelial cell migration | |
| high-density lipoprotein particle clearance | |
| very-low-density lipoprotein particle clearance | |
| chylomicron remnant clearance | |
| low-density lipoprotein particle remodeling | |
| high-density lipoprotein particle remodeling | |
| very-low-density lipoprotein particle remodeling | |
| high-density lipoprotein particle assembly | |
| aging | |
| cell death | |
| maintenance of location in cell | |
| regulation of Cdc42 protein signal transduction | |
| nitric oxide mediated signal transduction | |
| cGMP-mediated signaling | |
| G-protein coupled receptor signaling pathway | |
| phototransduction, visible light | |
| synaptic transmission, cholinergic | |
| regulation of neuronal synaptic plasticity | |
| cellular calcium ion homeostasis | |
| negative regulation of neuron apoptotic process | |
| negative regulation of endothelial cell proliferation | |
| lipid transport | |
| phospholipid efflux | |
| reverse cholesterol transport | |
| cholesterol efflux | |
| positive regulation of cholesterol efflux | |
| response to reactive oxygen species | |
| response to retinoic acid | |
| response to ethanol | |
| cellular response to cholesterol | |
| response to insulin | |
| cellular response to growth factor stimulus | |
| cellular response to interleukin-1 | |
| response to oxidative stress | |
| negative regulation of inflammatory response | |
| positive regulation of membrane protein ectodomain proteolysis | |
| positive regulation of low-density lipoprotein particle receptor catabolic process | |
| regulation of gene expression | |
| positive regulation of catalytic activity | |
| lipoprotein biosynthetic process | |
| lipoprotein metabolic process | |
| lipoprotein catabolic process | |
| transport | |
| intracellular transport | |
| receptor-mediated endocytosis | |
| cytoskeleton organization | |
| protein localization | |
| lipid homeostasis | |
| cholesterol homeostasis |
| Pathway | Alzheimer's Disease Overview |
|---|---|
| Ca2+ Toxicity in Alzheimer's Disease | |
| Mechanism of Amyloid beta Clearance | |
| Proteins Involved in Pathogenesis of Alzheimer's Disease | |
| Proteins Involved in Pathogenesis of Parkinson's Disease | |
| Traffic and Degradation of Extracellular Amyloid beta in Alzheimer's Disease | |
| Amyloid beta and APP Intracellular Transport in Alzheimer's Disease | |
| APP and Glutamate Signaling-Related Neuronal Dysfunction in Alzheimer's Disease | |
| Proteins Involved in Pathogenesis of Diabetes Mellitus Type 2 | |
| Proteins Involved in Pathogenesis of Atherosclerosis | |
| Impairment of BMP and TGF-beta Signaling in Familial and Idiopathic Pulmonary Arterial Hypertension | |
| Proteins Involved in Pathogenesis of Pulmonary Hypertension | |
| Proteins Involved in Pathogenesis of HIV Type 1 Infection | |
| Proteins Involved in Pathogenesis of Amyotrophic Lateral Sclerosis | |
| Proteins Involved in Pathogenesis of Epilepsy | |
| Proteins Involved in Pathogenesis of Myocardial Ischemia | |
| Adenosine Expression Targets | |
| Alzheimer disease pathway | |
| Alzheimer disease pathway |
| Group | Lipid transport |
|---|---|
| lipid metabolic process | |
| small molecule metabolic process | |
| negative regulation of cholesterol biosynthetic process | |
| positive regulation of cGMP biosynthetic process | |
| negative regulation of MAP kinase activity | |
| cholesterol catabolic process | |
| positive regulation of nitric-oxide synthase activity | |
| positive regulation of cholesterol esterification | |
| triglyceride metabolic process | |
| retinoid metabolic process | |
| cholesterol metabolic process | |
| response to dietary excess | |
| negative regulation of blood coagulation | |
| negative regulation of platelet activation | |
| vasodilation | |
| cardiovascular system development | |
| artery morphogenesis | |
| oligodendrocyte differentiation | |
| positive regulation of axon extension | |
| regulation of axon extension | |
| neuron projection regeneration | |
| axon regeneration | |
| peripheral nervous system axon regeneration | |
| negative regulation of blood vessel endothelial cell migration | |
| high-density lipoprotein particle clearance | |
| very-low-density lipoprotein particle clearance | |
| chylomicron remnant clearance | |
| low-density lipoprotein particle remodeling | |
| high-density lipoprotein particle remodeling | |
| very-low-density lipoprotein particle remodeling | |
| high-density lipoprotein particle assembly | |
| aging | |
| cell death | |
| maintenance of location in cell | |
| regulation of Cdc42 protein signal transduction | |
| nitric oxide mediated signal transduction | |
| cGMP-mediated signaling | |
| G-protein coupled receptor signaling pathway | |
| phototransduction, visible light | |
| synaptic transmission, cholinergic | |
| regulation of neuronal synaptic plasticity | |
| cellular calcium ion homeostasis | |
| negative regulation of neuron apoptotic process | |
| negative regulation of endothelial cell proliferation | |
| lipid transport | |
| phospholipid efflux | |
| reverse cholesterol transport | |
| cholesterol transporter activity | |
| cholesterol efflux | |
| positive regulation of cholesterol efflux | |
| lipid transporter activity | |
| response to reactive oxygen species | |
| response to retinoic acid | |
| response to ethanol | |
| cellular response to cholesterol | |
| response to insulin | |
| cellular response to growth factor stimulus | |
| cellular response to interleukin-1 | |
| response to oxidative stress | |
| negative regulation of inflammatory response | |
| positive regulation of membrane protein ectodomain proteolysis | |
| positive regulation of low-density lipoprotein particle receptor catabolic process | |
| regulation of gene expression | |
| positive regulation of catalytic activity | |
| phosphatidylcholine-sterol O-acyltransferase activator activity | |
| lipoprotein biosynthetic process | |
| lipoprotein metabolic process | |
| lipoprotein catabolic process | |
| transport | |
| intracellular transport | |
| receptor-mediated endocytosis | |
| cytoskeleton organization | |
| protein localization | |
| lipid homeostasis | |
| cholesterol homeostasis | |
| antioxidant activity | |
| lipid binding | |
| hydroxyapatite binding | |
| very-low-density lipoprotein particle receptor binding | |
| low-density lipoprotein particle receptor binding | |
| tau protein binding | |
| protein homodimerization activity | |
| protein heterodimerization activity | |
| phospholipid binding | |
| heparin binding | |
| beta-amyloid binding | |
| metal chelating activity | |
| lipoprotein particle binding | |
| extracellular region | |
| extrinsic component of external side of plasma membrane | |
| nuclear envelope | |
| microtubule | |
| endocytic vesicle lumen | |
| low-density lipoprotein particle | |
| high-density lipoprotein particle | |
| chylomicron | |
| discoidal high-density lipoprotein particle | |
| very-low-density lipoprotein particle | |
| intermediate-density lipoprotein particle | |
| cell surface | |
| plasma membrane | |
| cytoplasm | |
| Golgi apparatus | |
| endoplasmic reticulum | |
| endosome | |
| lysosome | |
| late endosome | |
| early endosome | |
| dendrite | |
| neuronal cell body | |
| extracellular space | |
| Genes with Mutations Associated with Alzheimer's Disease | |
| Genes with Mutations Associated with Psoriasis | |
| Genes with Mutations Associated with Atherosclerosis | |
| Secreted proteins | |
| Biofluids assayable substances |
| LocusLink ID | 99 |
|---|---|
| 348 | |
| 11816 | |
| 25728 |
| Cell Localization | Plasma membrane |
|---|---|
| Secreted |
| GO ID | 0016209 |
|---|---|
| 0001540 | |
| 0017127 | |
| 0008201 | |
| 0046848 | |
| 0008289 | |
| 0005319 | |
| 0071813 | |
| 0050750 | |
| 0046911 | |
| 0060228 | |
| 0005543 | |
| 0046982 | |
| 0042803 | |
| 0048156 | |
| 0070326 | |
| 0007186 | |
| 0007568 | |
| 0048844 | |
| 0019934 | |
| 0008219 | |
| 0006874 | |
| 0071397 | |
| 0071363 | |
| 0071347 | |
| 0006707 | |
| 0033344 | |
| 0042632 | |
| 0008203 | |
| 0034382 | |
| 0007010 | |
| 0034380 | |
| 0034384 | |
| 0034375 | |
| 0046907 | |
| 0042158 | |
| 0042159 | |
| 0042157 | |
| 0034374 | |
| 0051651 | |
| 0043407 | |
| 0030195 | |
| 0043537 | |
| 0045541 | |
| 0001937 | |
| 0050728 | |
| 0043524 | |
| 0010544 | |
| 0007263 | |
| 0048709 | |
| 0014012 | |
| 0033700 | |
| 0007603 | |
| 0045773 | |
| 0030828 | |
| 0010875 | |
| 0010873 | |
| 0032805 | |
| 0051044 | |
| 0051000 | |
| 0006898 | |
| 0032489 | |
| 0030516 | |
| 0010468 | |
| 0048168 | |
| 0002021 | |
| 0045471 | |
| 0032868 | |
| 0000302 | |
| 0032526 | |
| 0001523 | |
| 0043691 | |
| 0044281 | |
| 0007271 | |
| 0006641 | |
| 0042311 | |
| 0034447 | |
| 0034372 | |
| 0005794 | |
| 0042627 | |
| 0005737 | |
| 0030425 | |
| 0005769 | |
| 0071682 | |
| 0005576 | |
| 0005615 | |
| 0031232 | |
| 0034364 | |
| 0034363 | |
| 0005770 | |
| 0034362 | |
| 0043025 | |
| 0005886 | |
| 0034361 | |
| 0031103 | |
| 0072358 | |
| 0055088 | |
| 0006629 | |
| 0006869 | |
| 0043085 | |
| 0008104 | |
| 0006979 | |
| 0006810 | |
| 0005874 | |
| 0031102 | |
| 0009986 | |
| 0034365 | |
| 0005783 | |
| 0005768 | |
| 0005764 | |
| 0005635 |
| Alias | AD2 |
|---|---|
| LPG | |
| LDLCQ5 | |
| apolipoprotein E | |
| apo-E | |
| apolipoprotein E3 | |
| AI255918 | |
| APOEA | |
| OTTHUMP00000197075 | |
| apoE4 | |
| apoE3 | |
| Alzheimer disease 2 | |
| Alzheimer disease-2 | |
| OTTHUMP00000197077 | |
| OTTHUMP00000197076 | |
| APOE | |
| APE_HUMAN | |
| MGC1571 |
| Mouse chromosome position | 7 9.94 cM |
|---|
| OMIM ID | 107741 |
|---|---|
| 603075 | |
| 104310 | |
| 606889 | |
| 611771 | |
| 269600 |
| Rat chromosome position | 1q21 |
|---|
| Hugo ID | 613 |
|---|
| Human chromosome position | 19q13.2 |
|---|
| Swiss-Prot Accession | P02649 |
|---|---|
| P08226 | |
| Q3TXU4 | |
| P02650 | |
| B2RC15 | |
| C0JYY5 | |
| Q9P2S4 |
| PIR ID | A26189 |
|---|---|
| A92478 | |
| JU0036 |
| Unigene ID | Hs.654439 |
|---|---|
| Mm.305152 | |
| Rn.32351 |
| KEGG ID | hsa:348 |
|---|---|
| mmu:11816 | |
| rno:25728 |
| Swiss-Prot ID | APOE_RAT |
|---|---|
| APOE_HUMAN | |
| APOE_MOUSE |
| Ensembl ID | ENSG00000130203 |
|---|---|
| ENSP00000252486 | |
| ENST00000252486 | |
| ENSMUSG00000002985 | |
| ENSMUSP00000133302 | |
| ENSMUST00000174064 | |
| ENSMUSP00000133371 | |
| ENSMUST00000173739 | |
| ENSRNOG00000018454 | |
| ENSRNOP00000050968 | |
| ENSRNOT00000041891 |
| Homologene ID | 30951 |
|---|
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| MGI ID | 88057 |
|---|
| RGD ID | 2138 |
|---|
| MedScan ID | 99 |
|---|